S&C Advises Biohaven in $287.5 Million Registered Common Shares Offering

Biohaven completed a registered offering of $287.5 million of common shares, which included the full exercise of the underwriters' option to purchase additional common shares.

J.P. Morgan, Morgan Stanley, Jefferies and TD Cowen acted as the joint lead bookrunning managers of the offering. The net proceeds from the offering will be used for general corporate purposes.

Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology.

The S&C team advising Biohaven included Bob Downes, Katya Roze, Gao Song and Robert Okada. Davis Wang, John Jo and Eli Dubin advised on tax matters.

This is S&C's third registered equity deal and the latest transaction in the Firm's longstanding relationship with Biohaven, including its spin-off in connection with the $11.6 billion acquisition of Biohaven Pharma by Pfizer in 2022.